Monday, March 03, 2025 | 06:31 AM ISTहिंदी में पढें

Home / Markets / News / Cipla surges 15% on USFDA nod for first generic Proventil HFA inhaler

Cipla surges 15% on USFDA nod for first generic Proventil HFA inhaler

Proventil HFA (albuterol sulfate) metered-dose inhaler is used for the treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms.

R&D spend went up from 6 per cent of operating income in FY13 to 9 per cent of operating income in FY17. After that there has been a steady decline in the past two financial years

Premium

Albuterol is the first generic metered dose inhaler of Proventil HFA Inhalation Aerosol ever approved by FDA. (Representative image)

SI Reporter Mumbai

2 min read Last Updated : Apr 09 2020 | 9:50 AM IST

Shares of Cipla were locked in the upper circuit of 15 per cent at Rs 590, also its 52-week high on the BSE on Thursday after the drug firm received United States Food and Drug Administration's (USFDA) nod for the first generic Proventil HFA (albuterol sulfate) metered dose inhaler, used for conditions such as asthma.

Till 09:29 am, a combined 1.79 million shares traded and there were pending buy orders for 744,000 shares on the NSE and BSE, the exchange data shows. Cipla is trading in future and option (F&O) segment and the F&O stocks don't have any circuit

Topics : Cipla Markets Sensex Nifty Buzzing stocks

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in